Condition: Breast Neoplasms · Sponsor: Novartis Pharmaceuticals
This non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence, as well as patient compliance and quality of life.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Wiener Neustadt, Lower Austria, Austria | Recruiting |
| Novartis Investigative Site | Innsbruck, Tyrol, Austria | Recruiting |
| Novartis Investigative Site | Linz, Upper Austria, Austria | Recruiting |
| Novartis Investigative Site | Graz, Austria | Recruiting |
| Novartis Investigative Site | Klagenfurt, Austria | Recruiting |
| Novartis Investigative Site | Leoben, Austria | Recruiting |
| Novartis Investigative Site | Schwaz, Austria | Recruiting |
| Novartis Investigative Site | Steyr, Austria | Recruiting |
| Novartis Investigative Site | Vienna, Austria | Recruiting |
| Novartis Investigative Site | Vienna, Austria | Recruiting |
| Novartis Investigative Site | Vienna, Austria | Recruiting |
| Novartis Investigative Site | Vienna, Austria | Recruiting |
+ 272 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06830720